SCHEMBL24324162

SCHEMBL24324162

CN1CCN(C(=O)[C@H]2CCCNC2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
HTT P42858 1/20 0.56
SLC6A1 P30531 2/20 0.50
TSHR P16473 2/20 0.50
SLC6A11 P48066 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
SLC6A13 Q9NSD5 1/20 0.50
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
ATM Q13315 1/20 0.49
CYP2D6 P10635 1/20 0.49
ALDH1A1 P00352 2/20 0.48
CHRNB2 P17787 1/20 0.46
CHRNA3 P32297 1/20 0.46
CHRNA4 P43681 1/20 0.46
CHRNB3 Q05901 1/20 0.46
CHRNA6 Q15825 1/20 0.46
HSD11B1 P28845 1/20 0.42
PARP1 P09874 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006073 1.00 LMNA (0.58) LMNAHTTSLC6A1TSHRSLC6A11
SCHEMBL9763185 0.91 SLC6A1 (0.59) LMNAHTTSLC6A1TSHRSLC6A11
SCHEMBL27862944 0.90 HTT (0.54) LMNAHTTTSHRKMT2AALDH1A1
SCHEMBL16134883 0.90 HTT (0.54) LMNAHTTTSHRKMT2AALDH1A1
SCHEMBL25565526 0.90 HTT (0.54) LMNAHTTTSHRKMT2AALDH1A1
Bromide SCHEMBL9763700 0.90 SLC6A1 (0.57) LMNAHTTSLC6A1TSHRSLC6A11
SCHEMBL2655363 0.86 SLC6A1 (0.57) LMNAHTTSLC6A1TSHRSLC6A11
SCHEMBL20811833 0.86 SLC6A1 (0.57) LMNAHTTSLC6A1TSHRSLC6A11
SCHEMBL16584420 0.86 SLC6A1 (0.57) LMNAHTTSLC6A1TSHRSLC6A11
Hydrochloric Acid SCHEMBL16584136 0.84 SLC6A1 (0.55) LMNAHTTSLC6A1TSHRSLC6A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN LMNA 1889/4885HTT 70/4885SLC6A1 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.